Radiation dosimetry is a necessary ingredient for a perfectly mixed molecular radiotherapy cocktail

Lu-DOTATATE: which is abetter therapy option?” [1], which reported on a peptidereceptor radionuclide therapy (PRRT) clinical trial of 50patients with disseminated neuroendocrine tumours (NET).The accompanying editorial [2] draws attention to the crit-ical issue that in order to compare the results between thegroups, patients should be properly randomised and poten-tial sources of bias should be thoroughly considered. Wewould contend that there are many potential sources of biasin this study, in addition to that caused by the sequentialnature of the treatments, whereby all patients receiving